Biosimilars
What defines a biosimilar
Biosimilars
A biosimilar is a biologic medicine that matches an approved reference product in terms of quality, safety, and clinical performance. Achieving this requires a deep understanding of molecular structure, biological function, and the impact of manufacturing conditions on product behavior.
Small differences in expression systems, purification steps, or formulation can influence outcomes. That is why biosimilar development depends on advanced analytics, tightly controlled processes, and a comprehensive comparability strategy.
Number of changes in the production of some biological drugs
The Nature of Biological Variation Because biological medicines are produced in living cells, minor molecular variations are inevitable. These variations occur not only between a biosimilar and its reference product but also between different batches of the same reference medicine. These differences are considered clinically equivalent and do not impact the drug's safety or efficacy. Comparison of Manufacturing Changes Manufacturing changes are common in the production of all biologics. For instance, reference drugs such as Humira and Remicade have undergone approximately 30 and 35 documented manufacturing changes, respectively, throughout their lifecycles. Such fluctuations are a standard characteristic of biological production.
Distinguishing Biosimilars from Generics
Biosimilars are fundamentally different from generic drugs. While generics are chemically synthesized and have simple, identical structures to the original drug, biologics are large, three-dimensional, and highly sensitive molecules.
They are scientific equivalents, not exact chemical copies.
They are produced in living cells, leading to natural variability.
They require rigorous clinical proof of similarity rather than just chemical identity.
The Development Process
The core objective of biosimilar development is to demonstrate "high similarity" to the reference product through a step-by-step scientific evaluation:
Analytical Studies
Detailed characterization of physicochemical and biological properties (e.g., structure, purity, and biological activity).
Pharmacokinetics (PK) and Pharmacodynamics (PD)
Comparing how the drug behaves and affects the body relative to the reference product.
Comparative Clinical Trials
Confirming that there are no clinically meaningful differences in human safety and effectiveness.
The Value of Biosimilars
Biological therapies are highly effective but often carry high costs, straining healthcare budgets globally. Biosimilars address this challenge by introducing competition into the biological medicine market.
Benefits include:
- Reduced Treatment Costs: Lowering the financial burden on patients and providers.
- Increased Access: Enabling more patients to receive advanced therapies.
- Healthcare Sustainability: Supporting the long-term viability of national health systems.
